Background: Although we know that the quality of life generally improves after left ventricular assist device (LVAD) implantation, we know little about how symptoms change in response to LVAD. Methods: The purpose of this study was to compare the changes in symptoms between bridge and destination therapy patients as part of a prospective cohort study. Physical (dyspnea and wake disturbances) and affective symptoms (depression and anxiety) were measured before LVAD and at 1, 3, and 6 months after LVAD. Multiphase growth modeling was used to capture the 2 major phases of change: initial improvements between preimplant and 1 month after LVAD and subsequent improvements between 1 and 6 months after LVAD. Results: The sample included 64 bridge and 22 destination therapy patients as the preimplant strategy. Destination patients had worse preimplant dyspnea and wake disturbances, and they experienced greater initial improvements in these symptoms compared with bridge patients (all P G .05); subsequent change in both symptoms were similar between groups (both P 9 .05). Destination patients had worse preimplant depression (P = .042) but experienced similar initial and subsequent improvements in depression in response to LVAD compared with bridge patients (both P 9 .05). Destination patients had similar preimplant anxiety (P = .279) but experienced less initial and greater subsequent improvements in anxiety after LVAD compared with bridge patients (both P G .05). Conclusion: There are many differences in the magnitude and timing of change in symptom responses to LVAD between bridge and destination therapy patients. Detailed information on changes in specific symptoms may better inform shared decision-making regarding LVAD.
Health-related quality of life (HRQOL) is also known to improve with LVAD therapy irrespective of age 8 or HF severity. 9 Because there is no LVAD-specific measure of HRQOL 10 and because HRQOL is poorly defined in advanced HF, 11 it is often used as a broad and catch-all term that can be difficult for providers and patients to appreciate. 12 In addition to poor HRQOL, HF is also known to be associated with burdensome physical symptoms such as dyspnea 13 and wake disturbances 14 as well as affective symptoms such as depression and anxiety. 15, 16 Symptoms are important in HF because they are the main progenitor of health care usage 17 and independent predictors of event risk. 18, 19 Compared with our extensive knowledge about HRQOL, however, we know little about how specific symptoms change in response to LVAD in general, 10, 20 or comparing LVAD therapy as a bridge or destination therapy in particular. A more detailed understanding of symptom responses to LVAD therapy will allow us to better support shared decision-making, provide sufficient education to patients and families about what to expect, and tailor monitoring strategies to identify and ameliorate the barriers to optimal patient-reported outcomes. The purpose of this study was to characterize and compare the changes in physical and affective symptoms among adults undergoing LVAD implantation as bridge to heart transplantation/decision or as destination therapy from preimplantation through the first 6 months after LVAD implantation.
Methods

Design
Profiling Biobehavioral Responses to Mechanical Support in Advanced Heart Failure is a US National Institutes of HealthYsponsored prospective cohort study designed, in part, to better characterize patient-reported outcomes in responses to LVAD. The full background and design of the Profiling Biobehavioral Responses to Mechanical Support in Advanced Heart Failure study have been reported in detail elsewhere. 21 In brief, adults (Q21 years) who were undergoing LVAD with a commercially available and US Food and Drug AdministrationYapproved continuous-flow LVAD as a bridge to transplantation/decision or as destination therapy were approached for participation, enrolled before the initiation of LVAD, and followed for 6 months after LVAD implantation. All participants met the criteria for Interagency Registry for Mechanically Assisted Circulatory Support profiles 1 to 4. 7 The patients were not eligible if they had a heart transplantation or previous LVAD before enrollment, major psychiatric illness, or documented major cognitive impairment such as Alzheimer"s disease or if they had concomitant terminal illness that impeded participation in a 6-month study. For the purposes of this study, the patients were identified as requiring an LVAD as bridge (ie, bridge to transplantation or decision) or destination therapy as the preimplantation strategy designated by a multidisciplinary advanced HF section committee. The participants were recruited through a single center between April 2012 and December 2015. Written informed consent was obtained from all study participants, and the study was reviewed and approved by our institutional review board.
Data Collection
Our perspectives on patient-reported outcomes in response to LVAD were informed by the Patient-Reported Outcomes Measurement Information System Adult Health Domain Framework. 22 Thus, in addition to our use of HRQOL as a broad general health outcome, we chose valid and reliable measures of common physical health (ie, symptoms of dyspnea and wake disturbances) and mental health (ie, affective symptom of depression and anxiety) as more perceptible patient-reported outcomes. The following measures were used before LVAD (median of 5 days preimplant) and at 1, 3, and 6 months after LVAD.
Heart failure HRQOL was measured with the Kansas City Cardiomyopathy Questionnaire (KCCQ). 12 The KCCQ HRQOL score is derived from 3 items focused on how HF has limited enjoyment of life, how the patient would feel if they had to spend the rest of their life with HF the way it is right now, and how often the patient felt discouraged or down in the dumps because of HF; scores on the KCCQ HRQOL range from 0 to 100 with higher scores reflecting better HRQOL. 12 Cronbach ! on the 3-item HRQOL scale was 0.63 in this study. There is no LVAD-specific measure of HRQOL; hence, we included the KCCQ HRQOL score for comparison to other studies because it is used extensively in LVAD studies and often as the only patient-reported outcome. In general, the KCCQ is more sensitive to change in clinical status compared with both other HF-specific 23 and general measures of HRQOL. 24 Overall, however, the KCCQ has sufficient predictive validity only when the risk of clinical events is low, not when patients have a high risk of death or hospitalization such as in advanced HF. 25 Dyspnea was measured using the Heart Failure Somatic Perception Scale (HFSPS). 26 The HFSPS asks about how much the participant was bothered by common HF symptoms during the last week and provides 6 response options ranging from 0 (not at all) to 5 (extremely bothersome). The HFSPS has a 6-item subscale for dyspnea that was used in this analysis (HFSPS dyspnea; range, 0Y30; higher scores indicate worse dyspnea). 27 Cronbach ! on the HFSPS dyspnea scale was 0.89 in this study.
Wake disturbances were measured using the 8-item Epworth Sleepiness Scale (ESS). 28 The ESS asks the respondents to rate how likely they would be to fall asleep in 8 situations by choosing response options that range from 0 (would never fall asleep) to 3 (high chance). The ESS correlates significantly with sleep latency measures, and the scores distinguish normal sleep patterns, idiopathic hypersomnia, and insomnia. 28 Cronbach ! was 0.89 in this study.
Depression was measured using the 9-item Patient Health Questionnaire (PHQ9). 29 The PHQ9 scores each of the 9-related Diagnostic and Statistical Manual-IV criteria providing 4 response options ranging from 0 (not at all) to 3 (nearly every day). The PHQ9 scores of 5, 10, 15, and 20 are indicative of mild, moderate, moderately severe, and severe depression, respectively. 29 Cronbach ! on the PHQ9 was 0.82 in this study.
Anxiety was measured using the Brief Symptom Inventory (BSI). 30 The BSI asks about feelings during the past 7 days and provides 5 response options ranging from 0 (no) to 4 (extreme). Subscale scores (ranging from 0 to 4) are calculated by adding the ratings and dividing the total by the number of items in the subscale, with higher scores indicating higher distress. Cronbach ! on the BSI anxiety items was 0.85 in this study.
Statistical Analysis
Means and SDs or counts and proportions were used to describe the sample, and t and # 2 tests were used to compare characteristics between bridge and destination therapy patients. Latent growth curve modeling 31 was performed to estimate change in symptoms across 4 time points from preimplant to 6 months postimplant. We performed multiphase growth modeling 32, 33 to capture the 2 major phases of change in patient-reported outcomes observed previously in response to LVAD implantation: 34 initial improvements observed between preimplant and 1-month postimplant ($ 1 ) and subsequent improvements between 1 and 6 months postimplant ($ 2 ). Based on multiphase growth models, preimplant values are presented in means and SEs, and phases of change are presented as mean slope, SE of the slope, and the significance of change as well as Cohen's d (ie, standardized mean difference) to quantify the magnitude of change (0.2Y0.3 is a small effect, approximately 0.5 is a moderate effect, and Q0.8 is a large effect). 35 To test for differences in symptoms between bridge and destination patients, we then compared preimplant values and each phase of change by therapy type (results are reported in t tests [ie, mean/SE of difference between implant strategy] and P values); this approach takes into consideration the multiphase growth modeling estimates and uses full information maximum likelihood estimation to mitigate bias due to missing data. 36 Trajectory graphs were prepared to compare changes in symptoms by implant strategy. There is no standard approach for sample size considerations in growth modeling; with 4 symptom measurements, however, our n-to-items ratio exceeded the sample size recommendations for related approaches (10:1). 37 Because the formal tests of difference were independent mean tests, we were powered to detect moderate differences (ie, Cohen"s d Q 0.5) with an allocation ratio of approximately 3:1, assuming that ! is equals to 0.05 and power is equals to 0.80. All statistical analyses were performed using Stata v14 (College Station, Texas) or Mplus v7.31 (Los Angeles, California).
Results
Characteristics of the sample (N = 86) before LVAD are presented in Table 1 . The patients requiring an LVAD as bridge therapy were 15 years younger on average, and fewer had HF of ischemic etiology compared with destination therapy patients. Destination therapy patients had more complicated comorbid conditions including diabetes, kidney disease, and sleep-disordered breathing, and more were former smokers compared with bridge therapy patients. Although not statistically significant, more destination therapy patients had a history of depressive or anxiety disorders and were on routine psychotropic medications compared with bridge therapy patients.
Otherwise, the 2 groups had similar clinical hallmarks of advanced HF including dilated left ventricles with poor contractility, elevated right-and left-sided filling pressures, and reduced cardiac output. During 6 months of follow-up, 2 destination therapy patients died and another 2 required device exchanges; 3 bridge therapy patients died, 1 required a device exchange, and 8 were transplanted.
Over the course of 6 months, there were large and significant improvements in HRQOL in response to LVAD in both patient groups (Figure 1 ). Compared with bridge therapy patients, destination therapy patients had similar HRQOL before implantation (P = .111), but they experienced significantly greater initial improvement in HRQOL in response to LVAD (P = .048). Subsequent improvements in HRQOL beyond 1 month after LVAD were significant and small to moderate in effect size but were not different between bridge and destination therapy patients (P = .590).
There were large and significant improvements in dyspnea and moderate and significant improvements in wake disturbances in response to 6 months of LVAD in both groups (Figure 2 ). Destination therapy patients had worse dyspnea before implantation (P = .034) and experienced greater initial improvements in dyspnea in response to LVAD compared with bridge therapy patients (P = .012). Subsequent improvements in dyspnea beyond 1 month of LVAD were small in effect size, similar by therapy type (P = .588), and significant only for bridge therapy patients. Destination therapy patients had worse wake disturbances before implantation (P = .001) and experienced greater initial improvements in wake disturbances in response to LVAD compared with bridge therapy patients (P = .009). In fact, wake disturbances did not change at 1 month compared with preimplant for bridge therapy patients. Additional improvements in wake disturbances beyond 1 month of LVAD were significant, moderate in effect size, and similar between bridge and destination therapy patients (P = .523).
Depression and anxiety improved significantly in response to LVAD in both groups over the course of 6 months (Figure 3 ). Destination therapy patients had worse depression before implant (P = .042) but experienced similar initial (P = .420) and subsequent improvements (P = 0.188) in response to LVAD compared with bridge therapy patients. Improvements in depression beyond 1 month of LVAD were only significant for destination therapy patients. Destination therapy patients had similar anxiety before LVAD compared with bridge patients (P = .279), but they experienced less initial (P = .025) improvement and greater subsequent improvements (P = .003) in anxiety in response to LVAD compared with bridge therapy patients. Anxiety was not better at 1 month compared with preimplant for destination therapy patients, and anxiety did not improve beyond 1 month of LVAD for bridge therapy patients.
Discussion
We sought to characterize and compare changes in common symptoms in response to LVAD as bridge or destination therapy. In this sample of 86 adults undergoing LVAD, we observed large and significant improvements in dyspnea, wake disturbances, depression, and anxiety that, in many instances, were different comparing bridge versus destination therapy patients in both magnitude and in the timing of change. Destination therapy patients had similar preimplant anxiety but worse preimplant dyspnea, wake disturbances, and depression compared with bridge therapy patients. Destination therapy patients had greater initial (1 month) improvements in dyspnea and wake disturbance, similar initial improvements in depression, and smaller initial improvements in anxiety compared with bridge therapy patients. Finally, destination therapy patients had similar subsequent (1 to 6 months) improvements in dyspnea, wake disturbances, and depression and greater subsequent improvements in anxiety compared with bridge therapy patients. We are hopeful that our insights on specific symptom responses to LVAD that are concrete and tangible can facilitate shared decision-making and be complementary to the large body of literature on HRQOL in LVAD. Abbreviations: PCWP, pulmonary capillary wedge pressure; RAP, right atrial pressure; VO 2 max, maximal oxygen consumption.
Our findings of significant improvement in HRQOL in response to LVAD mirror the early and sustained changes reported previously 34 with a few notable exceptions. First, we have provided evidence that preimplant HRQOL is similar when comparing destination and bridge therapy patients. This is important because at the same time we have provided evidence that destination therapy patients have worse preimplant dyspnea, wake disturbances, and depression compared with bridge therapy patients. Hence, HRQOL cannot serve well as a catch-all patient-reported outcome if it does not capture significant differences in hallmark physical and affective symptoms associated with HF. Second, we provide evidence that the greatest gains in HRQOL occur within 1 month, and during this same time, destination therapy patients have much greater initial improvements in HRQOL compared with bridge therapy patients. Hence, the largest gains in HRQOL should be expected between preimplant and 1 month of LVAD, particularly among destination therapy patients, followed by significant but small to moderate improvements through 6 months of LVAD therapy. This also means that there may be room for improvement in optimizing HRQOL after 1 month. Our novel insights into one of the hallmark symptoms of HF, dyspnea, are important for a few reasons. First, communicating directly with patients and their families about what to expect regarding dyspnea may be more concrete than talking only about HRQOL in response to LVAD. For example, 1 talking point might be that on average patients have nearly half (bridge therapy) or less than one third (destination therapy) the amount of shortness of breath at 1 month of LVAD compared with what they are experiencing during preimplantation. Second, it is also important to note that whatever destination therapy patients gain in dyspnea reduction at 1 month will plateau compared with bridge therapy patients who will continue to have significant reductions in dyspnea after 1 month. This difference by implant strategy is important because destination therapy patients are living longer than ever with durable devices yet may live with a similar level of dyspnea they have just 1 month after LVAD. Indeed, this information derived from our novel findings may aid shared decision-making more effectively than a similar discussion about improvements in HRQOL, particularly for destination therapy patients.
Wake disturbances in HF are fascinating because they are common, are closely related to fatigue, and are often observable (eg, when the patient falls asleep during an exam). Previous work has provided evidence that wake disturbances are prevalent before and up to 6 months after LVAD. 38 To the best of our knowledge, however, our findings of worse wake disturbances preimplant and greater initial improvements in wake disturbances with destination therapy compared with bridge therapy patients are novel. After 1 month, subsequent reductions in wake disturbances were similar between bridge and destination therapy patients. Here again, changes in wake disturbances may be a more concrete way of describing the potential value of LVAD regarding patient-reported outcomes compared with HRQOL. Specifically, insight that destination therapy patients in particular are much less likely to fall asleep while reading, watching television, or talking with someone after LVAD compared with what they are experiencing preimplant may help them make better shared decisions. Moreover, there is room for improvement in minimizing wake disturbances after 1 month in both groups. Depression and anxiety have been shown to improve in an early and sustained fashion in response to LVAD in previous research. 39 We observed several new insights into depression and anxiety in response to LVAD. First, although depression was significantly worse preimplant among destination therapy compared with bridge patients, initial and subsequent improvements in depression in response to LVAD was similar between therapy types. Information that on average patients experience less than half the level of depression by 3 months compared with what they experience preimplant may help guide shared decisionmaking before LVAD. Said another way, by 3 months, the level of depression in both groups would be considered mild (5 of PHQ9) compared with preimplant depression that was in the moderate range (PHQ9 of 10). Second, depression and anxiety continued to improve significantly after 1 month in destination therapy patients, whereas there was a plateau in both depression and anxiety after 1 month for bridge therapy patients. It is unclear if therapy-related differences in how depression and anxiety change in response to LVAD reflect inherent variances in state (eg, the contribution of advanced HF) or trait (eg, the contribution of non-HF related factors) symptoms or simply differences between destination therapy patients who know that LVAD is their enduring therapy as opposed to bridge therapy patients who are hopeful for transplantation. Interestingly, recent work has provided evidence that LVAD-related changes in anxiety and depression are not dependent on the use of psychotropic medications. 39 Knowing that bridge therapy patients do not have significant improvements in depression and anxiety after 1 month, but have significant concomitant improvements in HRQOL and physical symptoms, may point to the need for strategyspecific cognitive therapy that has been shown to be helpful in other phases of HF. 40 There are both strengths and limitation to this research. This study is one of few studies that obtained detailed, valid, and reliable patient-reported measures of physical and affective symptoms before and after LVAD; hence, these results contribute to the emerging area of symptom science. An additional strength of this research is the use of a type of growth modeling that matches the 2 distinct phases of change in symptoms in response to LVAD. In addition to inherent limitations of observational research, this was a singlecenter study that included a sample mainly comprised of men and a relatively short follow-up period of 6 months of LVAD. Hence, more work will need to be done to codify or further refine these insights in future research. It is also our intention to identify the influence of demographic, clinical, and other treatment factors on the magnitude of change in symptoms in future reports. Finally, although the bridge versus destination therapy designation was helpful in characterizing differences and similarities of change in symptoms in this report, there are limitations to viewing this designation as mutually exclusive 41 that need to be considered when interpreting our findings.
Conclusion
Although LVAD is generally associated with significant improvements in physical and affective symptoms over time, there are many differences in the magnitude and timing of change in symptom responses to LVAD between bridge and destination therapy patients. Detailed information on changes in specific physical and affective symptoms may better inform shared LVAD decision-making compared with discussion about the generic patient-reported outcome of HRQOL.
h Beyond quality of life, there are marked improvements in physical and affective symptoms in response to LVADs. h There are many differences in the magnitude and timing of change in symptom responses to LVADs between bridge and destination therapy patients.
